AKEBIA THERAPEUTICS, INC. (AKBA)

Every figure this model derived for AKBA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,288,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 155,793,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 229,553,000 AssetsCurrent 2026-06-30
current liabilities 160,865,000 LiabilitiesCurrent 2026-06-30
equity 25,018,000 StockholdersEquity 2026-06-30
interest expense 6,080,000 InterestPaidNet 2025-12-31
ocf 41,552,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 219,060,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 13,314,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AKBA on one particular measure came for.

RatioValue
cash operating margin17.51
current ratio1.48
current ratio reported1.43
deferred revenue growth11.51
dilution pct21.92
fcf margin18.38
growth cv27.22
interest cover3.86
operating margin10.73
owner earnings margin12.3
revenue growth7.52
revenue growth per share-11.81
rule of 4018.25
sbc pct revenue6.08

What to be careful about

What this model itself distrusts about AKBA's figures. Written by the derivation as it ran, not added afterwards.